Nutlin-3a is the active enantiomer of Nutlin-3, an MDM2 antagonist that inhibits MDM2-p53 interaction. Nutlin-3a has antitumor activity. Cost-effective and quality-assured. View all Frequent failure and severe side effects of current sarcoma therapy warrants new therapeutic approaches. The small-molecule MDM2 antagonist Nutlin-3a activates the p53 pathway and efficiently induces apoptosis in tumours with amplified MDM2 gene and overexpression ... The p53MDM2/MDMX interaction represents a pivotal therapeutic target in oncology, with the cis-imidazoline scaffold of Nutlin-3a serving as the first nanomolar small-molecule MDM2 antagonist. This comprehensive review traces the evolution of Nutlin derivatives from lead optimization to clinical translation. The structural modification section discusses rational strategies to enhance ... Here, we evaluated whether hypoxia could render cancer cells insensitive to two MDM2 inhibitors with different potencies, nutlin-3a and navtemadlin. Interestingly, treatment with nutlin-3a even decreases p53 transcription which might be a feedback mechanism due to an increased amount of active p53. Taken together, these findings indicate that combination of archazolid and nutlin-3a might have an improved anti-tumor activity in wild type p53 cells compared to the two compounds alone. Antitumor activity of compound 3a was evaluated in vivo. (A) Photographs of tumor obtained from each treatment group excised on day 10. (n = 3, x SD, ** p < 0.01) (left); Mean tumor weight with ... This study evaluated ethosomes as a novel nanodelivery system for nutlin-3a, a known MDM2 inhibitor and activator of the p53 pathway, to improve nutlin-3as poor solubility, limiting its bio-distribution and therapeutic efficacy. The potential of nutlin-3a-loaded ethosomes was investigated on two in vitro models of melanoma: the HT144 cell line p53wild-type and the SK-MEL-28 cell line ...
As we can see from the illustration, 3A Has Antitumor Activity has many fascinating aspects to explore.
